checkAd

     517  0 Kommentare Theravance Announces FDA Advisory Committee to Review BREO(R) ELLIPTA(R) (FF/VI) for Asthma - Seite 3

    (THRX-G)

    Lesen Sie auch

    Contact Information:

    Eric d'Esparbes
    Senior Vice President and Chief Financial Officer
    650-238-9640
    investor.relations@thrxinc.com


    Seite 3 von 3

    Verfasst von Marketwired
    3 im Artikel enthaltene WerteIm Artikel enthaltene Werte
    Theravance Announces FDA Advisory Committee to Review BREO(R) ELLIPTA(R) (FF/VI) for Asthma - Seite 3 SOUTH SAN FRANCISCO, CA--(Marketwired - Feb 6, 2015) -  Theravance, Inc. (NASDAQ: THRX) today announced that on March 19, 2015, the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer